Last updated on July 23, 2022
India’s IPO market is once again buzzing with activity, this time with Gland Pharma IPO which is scheduled to open on 9 November. The upcoming offer is priced in the range of INR1,490 – 1,500 per share, which is above the expected level of INR1,300 per share. Nevertheless, the offer has attracted interest in the informal market. Check out the latest Gland Pharma IPO GMP (Grey Market Premium), Kostak rates and Subject to Sauda rates here.
Gland Pharma IPO details
| Subscription Dates | 9 – 11 November 2020 |
| Price Band | INR1,490 – 1,500 per share |
| Fresh issue | INR1,250 crore |
| Offer For Sale | 34,863,635 shares (INR5,194.68 – 5,229.55 crore) |
| Total IPO size | 34,863,635 shares (INR6,444.68 – 6,479.55 crore) |
| Minimum bid (lot size) | 10 shares |
| Face Value | INR1 per share |
| Retail Allocation | 35% |
| Listing On | NSE, BSE |
The injectables-focused company sells its products in 60 countries through its B2B partners and counts the US as its biggest market. Without a doubt, Gland Pharma’s financial performance is impressive and this is the reason behind the strong grey market premium. At the same time, the higher than expected pricing will limit the upside for IPO investors from allotment levels. On the other hand, the company’s big IPO size means that retail investors have better allotment chances this time.
Gland Pharma IPO GMP (Grey Market Premium) rates
| Date | GMP (in INR) | Kostak (in INR) | Subject to Sauda (in INR) |
| 19 Nov 2020 | 110 | 1,000 | – |
| 18 Nov 2020 | 130 | 1,200 | – |
| 17 Nov 2020 | 120 | 1,100 | – |
| 13 Nov 2020 | 70 | 600 | – |
| 12 Nov 2020 | 50 | 400 | – |
| 11 Nov 2020 | 25 | 200 | – |
| 10 Nov 2020 | 30 | 200 | – |
| 9 Nov 2020 | 60 | 400 | – |
| 7 Nov 2020 | 70 | 450 | – |
| 6 Nov 2020 | 90 | 550 | – |
| 5 Nov 2020 | 130 | 650 | 800 |
| 4 Nov 2020 | 170 | 800 | 1,200 |
| 3 Nov 2020 | 160 | 700 | 1,100 |
| 2 Nov 2020 | 150 | 700 | 1,100 |
Important points about IPO grey market and IPO GMP
IPO grey market movements may change very quickly and rates may be volatile. It is risky to base an investment decision on gray market IPO rates. Please refer to our research and analysis section.
Research has shown that retail investors are strongly influenced by market sentiment and as a result, are prone to overreaction, especially when it comes to IPO investing. Place your bets wisely!
IPO GMP rates are provided as sourced from market intelligence. Please note these IPO GMP rates may be different depending on geographies and markets.
We don’t trade into grey market nor do we facilitate buying or selling of IPO forms.
IPO GMP is the rate of premium an IPO commands per share in the informal grey market. This is the leading indicator of how the market perceives the IPO.
Kostak rate is the amount an investor gets by selling his/her IPO application in grey market. This is the amount an investor stands to gain, irrespective of allotment status.Subject to Sauda simply reflects the amount which an investor stands to get by selling his/her application for firm allotment. The key operative word here is firm allotment. In case of no allotment to the applicant, the sauda stands cancelled.
Retail investor should refrain from applying and paying such a huge premium. Of this sale 74% will go to the Phosun Phara China.
CHINA BUSINESS IS CONCERN
Avoid because of high premium and concert with china company.